Individualizing the Treatment of Type 2 Diabetes with a Focus on Cardiovascular Outcomes

Emerging clinical evidence regarding the impact of hyperglycemia on cardiovascular outcomes warrants that physicians utilize a multifaceted approach to decrease cardiovascular risk in patients with type 2 diabetes mellitus. However, the increasing array of antidiabetic agents requires education about the effective use of combination therapies to enhance patient outcomes. This educational activity will feature expert faculty discussing the effective use of therapeutic strategies in redefining the need to individualize treatment with a patient-first approach and assessing new as well as emerging clinical evidence to improve glycemic control, reducing cardiovascular risk


Please Note: this course is housed on Helio. Upon selecting 'Take Course,' you will be redirected to Register and to complete the activity.

Target Audience

This activity has been designed to address the educational needs of Endocrinologists and other health professionals who treat Type 2 Diabetes.

Learning Objectives

Upon proper completion of this activity, participants should be better able to:

  • Review the impact of antidiabetic medications in patients with multiple comorbidities such as hypertension, reduced renal function, obesity, and cardiovascular disease.
  • Incorporate individualized treatment strategies for patients with type 2 diabetes and cardiovascular risk factors based on the latest clinical evidence.
  • Apply clinical evidence on medications’ efficacy and safety when selecting monotherapy or combination therapy in patients with type 2 diabetes and cardiovascular risk factors.
Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Course summary
Available credit: 
  • 1.25 AMA
  • 1.25 Attendance
Course opens: 
10/01/2018
Course expires: 
10/01/2019
Cost:
$0.00

Vivian A. Fonseca, MD, FRCP, FACE
Contracted Research (Paid to Institution): Bayer, Boehringer Ingelheim

George Grunberger, MD, FACP, FACE
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi
Contracted Research: Eli Lilly, Medtronic, Novo Nordisk

Yehuda Handelsman, MD, FACP, FNLA, MACE 
Consulting Fee: Amarin, Amgen, Amylin, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Halozyme, Janssen, Merck, Novo Nordisk, Sanofi, Vivus
Speakers Bureau: Amarin, Amylin, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Novo Nordisk, Vivus
Contracted Research: Amgen, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Intarcia, Lexicon, Merck, Novo Nordisk, Sanofi, Takeda

Carol H. Wysham, MD, FACP, FACE
Consulting Fee: Abbott Medical Optics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi Aventis
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Insulet, Janssen, Novo Nordisk, Sanofi Aventis

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.25 AMA
  • 1.25 Attendance

Accreditation Period

Course opens: 
10/01/2018
Course expires: 
10/01/2019

Price

Cost:
$0.00
Please login or register to take this course.